Screener
aTyr Pharma ATYR D&A
D&A at other companies
Other financials
Where this comes from
Reported directly by aTyr Pharma in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The source filing: aTyr Pharma’s 10-Q, filed August 7, 2026. Open the filing →
- Filed
- Aug 7, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001339970-26-000053
FAQ
- What is aTyr Pharma's D&A?
- aTyr Pharma (ATYR) reported D&A of $168K in Q2 2026.
- How has aTyr Pharma's D&A changed year-over-year?
- aTyr Pharma's D&A increased by 1.2% year-over-year, from $166K to $168K.
- What is the long-term trend for aTyr Pharma's D&A?
- Over 4 years (2021 to 2025), aTyr Pharma's D&A has grown at a 8.7% compound annual growth rate (CAGR), from $475K to $664K.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about aTyr Pharma's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude